Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon secretion. It is unique among DPP-4 inhibitors as its primary route of elimination is non-renal (biliary/GI tract).
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
## Adult Dosing
* **Standard dose:** 5 mg orally once daily.
* **Maximum dose:** 5 mg per day.
## Pediatric Dosing
Safety and effectiveness in pediatric patients (younger than 18 years) have not been established. Use is generally not recommended.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment required.
* **Hepatic Impairment:** No dosage adjustment required.
* **Geriatric:** No dosage adjustment required.
## Contraindications
* History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* Type 1 diabetes or treatment of diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis, arthralgia.
* **Serious:** Pancreatitis (discontinue if suspected), bullous pemphigoid, severe joint pain, hypersensitivity reactions (urticaria, angioedema), and hypoglycemia (if used in combination with insulin or insulin secretagogues).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin systemic exposure, potentially reducing efficacy. Monitor glycemic control; consider an alternative agent or increased monitoring if co-administration is necessary.
* **Insulin/Secretagogues:** Increased risk of hypoglycemia; a reduction in the secretagogue or insulin dosage may be required.
## Monitoring
* **HbA1c:** Monitor every 3–6 months.
* **Blood Glucose:** Periodic self-monitoring is recommended, especially when initiating or adjusting therapy.
* **Pancreatitis:** Monitor for persistent, severe abdominal pain.
* **Skin:** Observe for development of blisters or erosions indicative of bullous pemphigoid.
## Clinical Pearls
* Linagliptin is the only DPP-4 inhibitor that does not strictly require dose adjustments for renal failure, making it a convenient choice for patients with chronic kidney disease.
* It is weight-neutral and associated with a low risk of hypoglycemia when used as monotherapy.
* Tablets may be taken with or without food.
* If a dose is missed, it should be taken as soon as possible; do not take double doses.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and local protocols vary. Always verify current prescribing information, package inserts, and hospital-specific clinical decision support tools before prescribing or administering medication.
